Table 2.
Investigations rates, and stage, histology and treatments from the baseline LDCT scan
| Number in total cohort (% of total lung cancers, n=36 (*except treatments) |
Number among those without a diagnosis of lung cancer (% of total participants without lung cancer, n=732) |
|
| Diagnostic or staging investigations | ||
| Positron emission tomography (PET) | 49 (136) | 16 (2.2) |
| Percutaneous non-lung biopsy | 5 (13.9) | 0 (0) |
| Other percutaneous biopsy | 6 (16.7) | 1 (0.1) |
| Cervical lymph node FNA | 2 (5.6) | 0 (0) |
| Fibreoptic bronchoscopy | 12 (33.3) | 9 (1.2) |
| Endobronchial ultrasound | 10 (27.8) | 1 (0.1) |
| Endoscopic ultrasound | 1 (2.8) | 0 (0) |
| VATS or open lung biopsy | 21 (58.3) | 2 (0.3) |
| Total: PET or invasive procedures | 29 (4.0) | |
| Histology | ||
| Invasive adenocarcinoma | 16 (44.4) | |
| Minimally invasive adenocarcinoma | 3 (8.3) | |
| Adenocarcinoma in situ | 1 (2.8) | |
| Squamous cell carcinoma | 6 (16.7) | |
| Mixed NSCLC (ie, adenosquamous) | 2 (5.6) | |
| Small cell lung cancer | 2 (5.6) | |
| Multiple or mixed histology (small cell + NSCLC) | 3 (8.3) | |
| Radiological diagnosis | 2 (5.6) | |
| Carcinoid | 1 (2.8) | |
| Stage (TNM 7th edition) | ||
| Stage I & II | 26 (72.2) | |
| Ia | 22 (61.1) | |
| Ib | 1 (2.8) | |
| IIa | 3 (8.3) | |
| IIb | 0 (0) | |
| IIIa | 6 (16.7) | |
| IIIb | 1 (2.8) | |
| IV | 3 (8.3) | |
| Treatments (NSCLC) (*% are of total NSCLC) | ||
| Curative intent | 27 (79.4) | |
| Sub-lobar resection | 11 (32.4) | |
| Lobectomy | 15 (44.1) | |
| SABR | 1 (2.9) | |
| Concurrent chemoradiation | 2 (5.9) | |
| Palliative chemotherapy±radiation | 4 (11.8) | |
| Surveillance | 1 (2.9) | |
| Treatments (SCLC) (*% are of total SCLC) | ||
| Radical chemoradiation | 2 (100) | |
CT, CT scan; DNA, did not attend; FNA, fine needle aspiration; GCSE, General Certificate of Secondary Education; LDCT, low-dose CT; LHC, lung health check; MDT, multidisciplinary team; NSCLC, non-small cell lung cancer; SABR, stereotactic ablative radiotherapy; SCLC, small cell lung cancer; TNM, tumour, node, metastases; UKLS, United Kingdom Lung Cancer Screening Trial; USPSTF, United States Preventive Services Task Force; VATS, video assisted thorascopic surgery.